Novartis's antibody drug Cosentyx did not achieve its primary endpoint in a Phase 3 clinical trial for treating giant cell arteritis, a rare autoimmune disorder affecting blood vessels. The trial’s failure to outperform placebo undermines hopes for expanding Cosentyx’s use beyond established indications and contrasts with competitive therapies from Roche and AbbVie already approved for this condition.